Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

Anti-TNF Therapy Correlated with Better Outcomes in IBD Patients with COVID-19

20 Dec 2021

Connie TANG

Share

This content is sponsored. It is intended for healthcare professionals only.

The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that have an increasing incidence and prevalence in different regions around the world.

Anti-TNF Therapy Correlated with Better Outcomes in IBD Patients with COVID-19

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026